Beta Drugs Financial Statements

Beta Drugs Quarterly Results

Switch to
Tabular Data
Graph
Switch to
Consolidated
Standalone
Y/e 31 Mar Mar-2021 Mar-2020 - -
Growth matrix (%)        
Revenue growth 27.90 -- -- --
Op profit growth 38.20 -- -- --
EBIT growth 26.20 -- -- --
Net profit growth 24.50 -- -- --
Profitability ratios (%)        
OPM 21.30 19.70 -- --
EBIT margin 15.80 16 -- --
Net profit margin 10.10 10.40 -- --
RoCE 22.20 -- -- --
RoNW 4.66 -- -- --
RoA 3.54 -- -- --
Per share ratios ()        
EPS 12.20 9.79 -- --
Dividend per share -- -- -- --
Cash EPS 5.05 5.88 -- --
Book value per share 71.40 59.40 -- --
Valuation ratios        
P/E 9.84 4.09 -- --
P/CEPS 23.80 6.80 -- --
P/B 1.68 0.67 -- --
EV/EBIDTA 4.85 3.04 -- --
Payout (%)        
Dividend payout -- -- -- --
Tax payout (26) (21) -- --
Liquidity ratios        
Debtor days 103 -- -- --
Inventory days 44.60 -- -- --
Creditor days (76) -- -- --
Leverage ratios        
Interest coverage (7.60) (5.60) -- --
Net debt / equity 0.10 0.30 -- --
Net debt / op. profit 0.28 0.96 -- --
Cost breakup ()        
Material costs (51) (49) -- --
Employee costs (9.40) (10) -- --
Other costs (19) (21) -- --
Switch to
Tabular Data
Graph
Switch to
Consolidated
Standalone
Y/e 31 Mar( In .Cr) Mar-2021 Mar-2020 - -
Revenue 116 90.80 -- --
yoy growth (%) 27.90 -- -- --
Raw materials (59) (44) -- --
As % of sales 50.60 48.80 -- --
Employee costs (11) (9.50) -- --
As % of sales 9.37 10.40 -- --
Other costs (22) (19) -- --
As % of sales 18.70 21 -- --
Operating profit 24.70 17.90 -- --
OPM 21.30 19.70 -- --
Depreciation (6.90) (3.80) -- --
Interest expense (2.40) (2.60) -- --
Other income 0.50 0.41 -- --
Profit before tax 16 12 -- --
Taxes (4.20) (2.60) -- --
Tax rate (26) (21) -- --
Minorities and other -- -- -- --
Adj. profit 11.70 9.42 -- --
Exceptional items -- -- -- --
Net profit 11.70 9.42 -- --
yoy growth (%) 24.50 -- -- --
NPM 10.10 10.40 -- --
Switch to
Tabular Data
Graph
Y/e 31 Mar ( In .Cr) Mar-2021 Mar-2020 - -
Profit before tax 16 12 -- --
Depreciation (6.90) (3.80) -- --
Tax paid (4.20) (2.60) -- --
Working capital 8.86 -- -- --
Other operating items -- -- -- --
Operating cashflow 13.70 -- -- --
Capital expenditure 2.85 -- -- --
Free cash flow 16.60 -- -- --
Equity raised 94.80 -- -- --
Investments 0.43 -- -- --
Debt financing/disposal (5.10) -- -- --
Dividends paid -- -- -- --
Other items -- -- -- --
Net in cash 107 -- -- --
Switch to
Tabular Data
Graph
Switch to
Consolidated
Standalone
Y/e 31 Mar ( In .Cr) Mar-2021 Mar-2020 Mar-2019 Mar-2018
Equity capital 9.61 9.61 8.65 8.65
Preference capital -- -- -- --
Reserves 59 47.50 32.30 24.20
Net worth 68.60 57.10 40.90 32.90
Minority interest
Debt 17.50 22.60 20 7.50
Deferred tax liabilities (net) -- -- 0.15 0.15
Total liabilities 86.10 79.70 61 40.50
Fixed assets 42.80 43.90 32.40 14.50
Intangible assets
Investments 0.78 0.35 0.35 --
Deferred tax asset (net) 0.65 0.17 0.29 --
Net working capital 31.40 29.90 24.70 14.10
Inventories 16 12.40 9.53 2.80
Inventory Days 50.40 49.60 -- --
Sundry debtors 33.90 31.90 25 14.40
Debtor days 106 128 -- --
Other current assets 13 13.10 11.80 5.89
Sundry creditors (22) (16) (16) (6.10)
Creditor days 67.80 65.70 -- --
Other current liabilities (9.90) (11) (6.10) (3)
Cash 10.40 5.39 3.30 11.90
Total assets 86.10 79.70 61 40.50
Switch to
Consolidated
Standalone


Beta Drugs Ltd Report not showing data
Open ZERO Brokerage Demat Account